Drug safety in breastfeeding: understanding the evidence
Most medications are compatible with breastfeeding. The decision to stop breastfeeding because of a medication is rarely necessary and frequently made without adequate evidence. The key metric is the relative infant dose (RID).
Relative infant dose (RID)
RID expresses the infant's dose via breast milk as a percentage of the mother's weight-adjusted dose. It's calculated as: (concentration in milk × infant feed volume) / maternal dose per kg. An RID below 10% is the widely accepted threshold for safety, it means the infant receives less than 10% of the maternal dose per kilogram. Most medications have an RID well below 5%. An RID above 25% warrants careful consideration.
Other factors that matter
Oral bioavailability matters, some drugs are poorly absorbed from the gut (e.g. heparin, insulin, vancomycin). Even if present in milk, they won't be absorbed by the infant. The infant's age matters, a neonate has immature metabolism; a 6-month-old has much greater metabolic capacity. Protein binding of the drug affects milk transfer, highly protein-bound drugs pass into milk poorly. Molecular weight matters, large molecules (biologics, heparin) don't pass into milk.
The default should be compatibility, not avoidance
The benefits of breastfeeding are significant and well-documented. Stopping breastfeeding has real costs for both mother and infant. Many package inserts say "not recommended in breastfeeding" based on a lack of data, not evidence of harm. For the most current and complete breastfeeding drug information, the NIH's LactMed database is the authoritative free resource. For pregnancy decisions, see our Pregnancy Drug Safety Checker. For drug half-life information relevant to timing feeds, use the Drug Half-Life Calculator.